Aspirin use was associated with a reduced overall cancer risk (adjusted OR 0.95; 95% CI 0.94 to 0.96), specifically for colorectal and digestive system cancers.
Case-Control (n=3,008,665)
Does aspirin use reduce the risk for cancer in the Taiwanese population?
Aspirin use is associated with a small but statistically significant reduction in overall, colorectal, and digestive system cancer risk in a large Taiwanese cohort.
Effect estimate: AOR 0.95 (95% CI 0.94 to 0.96)
Recently, studies have reported that aspirin has chemopreventive properties. In this study, we used the Taiwan NHI database, which covers a population of 23 million (99.99%) Taiwanese from 2001 to 2011. This was a case-control study which identified 601,733 patients using ICD-9-CM codes who were diagnosed with cancer. Each case with 4 eligible controls was matched for age, sex, and index date and adjusted for confounding factors. The observed overall cancer risk (adjusted OR (AOR), 0.95; 95% CI 0.94 to 0.96) reduced with aspirin use, specifically, colorectal (AOR, 0.97; 95% CI 0.94 to 0.99) and digestive system (AOR, 0.96; 95% CI 0.94 to 0.98) cancers. Findings from the Asian population would contribute to the discussion on aspirin's safety profile.
Iqbal et al. (2016) conducted a case-control in Cancer (n=3,008,665). Aspirin vs. No aspirin use (matched controls) was evaluated on Overall cancer risk (AOR 0.95, 95% CI 0.94 to 0.96). Aspirin use was associated with a reduced overall cancer risk (adjusted OR 0.95; 95% CI 0.94 to 0.96), specifically for colorectal and digestive system cancers.